Liver X receptors, nervous system, and lipidmetabolism

Journal of Endocrinological Investigation

Volumn 36, Issue 6, 2013, Pages 435-443

  Cermenati, G ^a   Brioschi, E ^a   Abbiati, F ^a   Melcangi, R C ^a   Caruso, D ^a   Mitro, N ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Central nervous system; Cholesterol; Fatty acids; Peripheral nervous system; Transcription factors

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN E; CHOLESTEROL; DESMOSTEROL; FARNESOID X RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; OXYSTEROL; PROGESTERONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TAU PROTEIN; TESTOSTERONE; UBIQUITIN PROTEIN LIGASE E3; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ADRENAL GLAND; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTE; BIOSYNTHESIS; BLOOD BRAIN BARRIER; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; ENERGY METABOLISM; GLIA CELL; GLIOBLASTOMA; HUMAN; HUNTINGTON CHOREA; LEARNING; LEWY BODY; LIPID STORAGE; LONG TERM POTENTIATION; MEMORY; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE CELL; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NIEMANN PICK DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL STATUS; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PHENOTYPE; REVIEW; SENILE PLAQUE; SMITH LEMLI OPITZ SYNDROME; SYSTEMIC CIRCULATION; UBIQUITINATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; CHOLESTEROL; ENERGY METABOLISM; HUMANS; LIPID METABOLISM; MICE; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; ORPHAN NUCLEAR RECEPTORS;

EID: 84881416880     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8941     Document Type: Review

References (93)

1. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 1995, 9: 1033-45.
2. Li AC, Glass CK. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 2004, 45: 2161-73.
3. Gilardi F, Viviani B, Galmozzi A, et al. Expression of sterol 27-hydroxylase in glial cells and its regulation by liver X receptor signaling. Neuroscience 2009, 164: 530-40.
4. Nelissen K, Mulder M, Smets I, et al. Liver X receptors regulate cholesterol homeostasis in oligodendrocytes. J Neurosci Res 2012, 90: 60-71.
5. Makoukji J, Shackleford G, Meffre D et al. Interplay between LXR and Wnt/β-catenin signaling in the negative regulation of peripheral myelin genes by oxysterols. J Neurosci 2011, 31: 9620-9.
6. Uppal H, Saini SP, Moschetta A, et al. Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 2007, 45: 422-32.
7. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383: 728-31.
8. Cummins CL, Mangelsdorf DJ. Liver X receptors and cholesterol homoeostasis: spotlight on the adrenal gland. Biochem Soc Trans 2006, 34: 1110-3.
9. Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med 2006, 57: 313-29.
10. Repa JJ, Liang G, Ou J et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000, 14: 2819-30.
11. Jurevics H, Morell PJ. Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 1995, 64: 895-901.
12. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001, 12: 105-12.
13. Saher G, Brügger B, Lappe-Siefke C, et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 2005, 8: 468-75.
14. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 2003, 278: 22980-8.
15. Björkhem I, Lütjohann D, Breuer O, Sakinis A, Wennmalm A. Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J Biol Chem 1997, 272: 30178-84.
16. Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci USA 2006, 103: 3869-74.
17. Fagan AM, Holtzman DM, Munson G, et al. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J Biol Chem 1999, 274: 30001-7.
18. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 1995, 136: 107-22.
19. Gordon I, Genis I, Grauer E, Sehayek E, Michaelson DM. Biochemical and cognitive studies of apolipoprotein-E-deficient mice. Mol Chem Neuropathol 1996, 28: 97-103.
20. Bojanic DD, Tarr PT, Gale GD, et al. Differential expression and function of ABCG1 and ABCG4 during development and aging. J Lipid Res 2010, 51: 169-81.
21. Chen J, Zhang X, Kusumo H, Costa LG, Guizzetti M. Cholesterol efflux is differentially regulated in neurons and astrocytes: implications for brain cholesterol homeostasis. Biochim Biophys Acta 2012, 1831: 263-75.
22. Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 2005, 280: 43224-35.
23. Tarr PT, Edwards PA. ABCG1 and ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. J Lipid Res 2008, 49: 169-82.
24. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325: 100-4.
25. Olsson PA, Korhonen L, Mercer EA, Lindholm D. MIR is a novel ERM-like protein that interacts with myosin regulatory light chain and inhibits neurite outgrowth. J Biol Chem 1999, 274: 36288-92.
26. Hong C, Duit S, Jalonen P, et al. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J Biol Chem 2010, 285: 19720-6.
27. Whitney KD, Watson MA, Collins JL, et al. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol 2002, 16: 1378-85.
28. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci U S A 2002, 99: 13878-83.
29. Rebeck GW. Cholesterol efflux as a critical component of Alzheimer's disease pathogenesis. J Mol Neurosci 2004, 23: 219-24.
30. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991, 6: 487-98.
31. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011, 377: 1019-31.
32. Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA 2007, 104: 10601-6.
33. CuiW, Sun Y, Wang Z, Xu C, Peng Y, Li R. Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP/PS1 transgenic mice. Neuroscience 2012, 210: 200-10.
34. Fitz NF, Cronican A, Pham T, et al. Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J Neurosci 2010, 30: 6862-72.
35. Peri A, Benvenuti S, Luciani P, Deledda C, Cellai I. Membrane cholesterol as a mediator of the neuroprotective effects of estrogens. Neuroscience 2011, 191: 107-17.
36. Cecchi C, Rosati F, Pensalfini A, et al. Seladin-1/DHCR24 protects neuroblastoma cells against Abeta toxicity by increasing membrane cholesterol content. J Cell Mol Med 2008, 12: 1990-2002.
37. Wang Y, Rogers PM, Stayrook KR, et al. The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene. Mol Pharmacol 2008, 74: 1716-21.
38. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39: 889-909.
39. Andersson S, Gustafsson N, Warner M, Gustafsson JA. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc Natl Acad Sci U S A 2005, 102: 3857-62.
40. Dai YB, Tan XJ, Wu WF, Warner M, Gustafsson JA. Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson disease. Proc Natl Acad Sci U S A 2012, 109: 13112-7.
41. Valenza M, Rigamonti D, Goffredo D, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 2005, 25: 9932-9.
42. Futter M, Diekmann H, Schoenmakers E, Sadiq O, Chatterjee K, Rubinsztein DC. Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors. J Med Genet 2009, 46: 438-46.
43. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454: 470-7.
44. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421: 744-8.
45. Korn T, Bettelli E, Gao W et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448: 484-7.
46. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995, 32: 121-82.
47. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23: 683-747.
48. Zhang-Gandhi CX, Drew PD. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J Neuroimmunol 2007, 183: 50-9.
49. Xu J, Wagoner G, Douglas JC, Drew PD. Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity. J Leukoc Biol 2009, 86: 401-9.
50. Hindinger C, Hinton DR, Kirwin SJ, et al. Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis. J Neurosci Res 2006, 84: 1225-34.
51. Cui G, Qin X, Wu L, et al. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Invest 2011, 121: 658-70.
52. Mitro N, Vargas L, Romeo R, Koder A, Saez E. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett 2007, 581: 1721-6.
53. th ed. New York: McGraw-Hill. 1995, 2625-39.
54. Repa JJ, Li H, Frank-Cannon TC, et al. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci 2007, 27: 14470-80.
55. Aqul A, Liu B, Ramirez CM et al. Unesterified cholesterol accumulation in late endosomes/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment. J Neurosci 2011, 31: 9404-13.
56. Sironi L, Mitro N, Cimino M, et al. Treatment with LXR agonists after focal cerebral ischemia prevents brain damage. FEBS Lett 2008, 582: 3396-400.
57. Morales JR, Ballesteros I, Deniz JM, et al. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation 2008, 118: 1450-9.
58. Cheng O, Ostrowski RP, Liu W, Zhang JH. Activation of liver X receptor reduces global ischemic brain injury by reduction of nuclear factor-kappaB. Neuroscience 2010, 166: 1101-9.
59. Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 2002, 52: 448-57.
60. Kim HJ, Fan X, Gabbi C, et al. Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc Natl Acad Sci USA 2008, 105: 2094-9.
61. Guo D, Reinitz F, Youssef M, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov 2011, 1: 442-56.
62. Lindegaard ML, Wassif CA, Vaisman B, et al. Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Lemli-Opitz syndrome. Hum Mol Genet 2008, 17: 3806-13.
63. Melcangi RC, Panzica GC. Neuroactive steroids: old players in a new game. Neuroscience 2006, 138: 733-9.
64. Melcangi RC, Garcia-Segura LM, Mensah-Nyagan AG. Neuroactive steroids: state of the art and new perspectives. Cell Mol Life Sci 2008, 65: 777-97.
65. Caruso D, Barron AM, Brown MA, et al. Age-related changes in neuroactive steroid levels in 3xTg-AD mice. Neurobiol Aging 2013, 34: 1080-9.
66. Melcangi CR, Garcia-Segura LM. Sex-specific therapeutic strategies based on neuroactive steroids: In search for innovative tools for neuroprotection. Horm Behav 2010, 57: 2-11.
67. Giatti S, Caruso D, Boraso M, et al. Neuroprotective effects of progesterone in chronic experimental autoimmune encephalomyelitis. J Neuroendocrinol 2012, 24: 851-61.
68. Caruso D, Scurati S, Roglio I, Nobbio L, Schenone A, Melcangi RC. Neuroactive Steroid Levels in a transgenic rat model of CMT1A Neuropathy. J Mol Neurosci 2008, 34: 249-53.
69. Melcangi RC, Panzica G, Garcia-Segura LM. Neuroactive steroids: focus on human brain. Neuroscience 2011, 191: 1-5.
70. Mitro N, Cermenati G, Giatti S, et al. LXR and TSPO as new therapeutic targets to increase the levels of neuroactive steroids in the central nervous system of diabetic animals. Neurochem Int 2012, 60: 616-21.
71. Obici S. Minireview: molecular targets for obesity therapy in the brain. Endocrinology 2009, 150: 2512-7.
72. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006, 443: 289-95.
73. Thaler JP, Yi CX, Schur EA, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 2012, 122: 153-62.
74. Frisardi V, Solfrizzi V, Seripa D et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 2010, 9: 399-417.
75. Kruse MS, Rey M, Vega MC, Coirini H. Alterations of LXRα and LXRβ expression in the hypothalamus of glucose-intolerant rats. J Endocrinol 2012, 215: 51-8.
76. Gabbi C, Kong X, Suzuki H, et al. Central diabetes insipidus associated with impaired renal aquaporin-1 expression in mice lacking liver X receptor β. Proc Natl Acad Sci U S A 2012, 109: 3030-4.
77. Laffitte BA, Chao LC, Li J et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A 2003, 100: 5419-24.
78. Zitzer H, Wente W, Brenner MB, et al. Sterol regulatory elementbinding protein 1 mediates liver X receptor-beta-induced increases in insulin secretion and insulin messenger ribonucleic acid levels. Endocrinology 2006, 147: 3898-905.
79. Gerin I, Dolinsky VW, Shackman JG, et al. LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem 2005, 280: 23024-31.
80. Efanov AM, Sewing S, Bokvist K, Gromada J. Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes 2004, 53 (Suppl 3): S75-8.
81. Grefhorst A, van Dijk TH, Hammer A, et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab 2005, 289: E829-38.
82. Loffler M, Bilban M, Reimers M, Waldhäusl W, Stulnig TM. Blood glucose-lowering nuclear rceptor agonists only partially normalize hepatic gene expression in db/db mice. J Pharmacol Exp Ther 2006, 316: 797-804.
83. Cao G, Liang Y, Broderick CL, et al. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 2003, 278: 1131-6.
84. Liu Y, Yan C, Wang Y, et al. Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology 2006, 147: 5061-8.
85. Commerford SR, Vargas L, Dorfman SE, et al. Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol Endocrinol 2007, 21: 3002-12.
86. Choe SS, Choi AH, Lee JW, et al. Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic beta-cells. Diabetes 2007, 56: 1534-43.
87. Chisholm JW, Hong J, Mills SA, Lawn RM. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 2003, 44: 2039-48.
88. Friedman JM. Obesity in the new millennium. Nature 2000, 404: 632-4.
89. Stulnig TM, Steffensen KR, Gao H, et al. Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol Pharmacol 2002, 62:1299-305.
90. Verheijen MH, Camargo N, Verdier V, et al. SCAP is required for timely and proper myelin membrane synthesis. Proc Natl Acad Sci U S A 2009, 106: 21383-8.
91. Cermenati G, Giatti S, Cavaletti G, et al. Activation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy. J Neurosci 2010, 30: 11896-901.
92. Giatti S, Pesaresi M, Cavaletti G, et al. Neuroprotective effects of a ligand of translocator protein-18 kDa (Ro5-4864) in experimental diabetic neuropathy. Neuroscience 2009, 164: 520-9.
93. Cermenati G, Abbiati F, Cermenati S et al. Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation. J Lipid Res 2012, 53: 300-10.